TUBIZE-FIN
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium. Show More...
-
Website http://www.financiere-tubize.be
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 126.00 EUR
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR 0.47 1.48 1.74 1.0 1.36 4.77 4.07 6.42 6.4 6.37 6.37 Dividends EUR 0.48 0.48 0.48 0.48 0.48 0.48 0.5 0.52 0.54 0.56 0.56 Payout Ratio % * 102.6 54.8 27.5 33.9 24.2 19.7 9.7 10.1 7.3 10.6 8.8 Shares Mil 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 45.0 Book Value Per Share * EUR 32.37 34.47 33.46 33.56 57.47 55.37 59.85 Free Cash Flow Per Share * EUR -0.03 -0.010 -0.03 -0.07 -0.07 -0.010 -0.010 -0.02 -0.02 -0.03 Return on Assets % 1.19 3.54 4.26 3.44 3.34 10.38 8.09 12.61 11.89 10.84 10.84 Financial Leverage (Average) 1.24 1.21 1.2 1.16 1.13 1.16 1.14 1.09 1.06 1.03 1.03 Return on Equity % 1.49 4.32 5.12 4.05 3.83 11.91 9.28 14.04 12.8 11.34 11.34 Return on Invested Capital % 2.11 3.6 5.05 4.07 3.87 10.73 8.34 12.82 12.01 10.89 10.89 Interest Coverage 2.34 7.11 7.21 8.12 34.45 34.36 58.98 121.37 238.01 238.01 Current Ratio 0.02 0.02 0.010 0.010 0.010 0.010 0.010 0.02 0.03 0.010 0.010 Quick Ratio 0.02 0.02 0.010 0.010 0.010 0.010 0.010 0.03 0.03 0.010 0.010 Debt/Equity 0.2 0.16 0.15 0.11 0.09 0.12 0.07 0.07 0.04 0.010 0.010